New drug shows promise for Long-Term psoriatic arthritis control
NCT ID NCT07223138
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 32 times
Summary
This study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. It involves about 1,560 adults who have already completed an earlier study of the same drug. The goal is to see if sonelokimab can safely control arthritis symptoms over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Mesa, Arizona, 85210, United States
-
Clinical Site
Phoenix, Arizona, 85032, United States
-
Clinical Site
Jonesboro, Arkansas, 72401, United States
-
Clinical Site
Upland, California, 91786, United States
-
Clinical Site
Avon Park, Florida, 33825, United States
-
Clinical Site
Clearwater, Florida, 33765, United States
-
Clinical Site
Middleburg Heights, Ohio, 44130, United States
-
Clinical Site
Duncansville, Pennsylvania, 16635, United States
-
Clinical Site
Memphis, Tennessee, 38119, United States
-
Clinical Site
Lubbock, Texas, 79424, United States
Conditions
Explore the condition pages connected to this study.